Xiaoji decoction induces apoptosis in lung cancer cells and M1 Macrophage polarization via the JAK1/STAT3/PD-L1 pathway.
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Xiaoji Decoction (XJD), a traditional Chinese herbal formula, has been used for decades to effectively treat non-small cell lung cancer (NSCLC), improving patients' quality of life and prolonging overall survival. Nevertheless, the molecular mechanisms responsible for the effectiveness of XJD on NSCLC remain largely unexplored.
AIM OF THE STUDY: This study aims to investigate the therapeutic effects of XJD in NSCLC and to elucidate the molecular mechanisms involved.
MATERIALS AND
METHODS
In vitro experiments were conducted by treating A549 cells with XJD at concentrations of 0, 6.25, 12.5, 25, and 50 mg/mL, and H1975 cells with XJD at concentrations of 0, 10, 20, 30, and 40 mg/mL. Ruxolitinib was used at a concentration of 10 μM. MTT assays were used to evaluate cell viability, and EdU assays were employed to measure cell proliferation. Apoptosis and cell cycle progression were analyzed by flow cytometry in vitro. The JAK1, p-STAT3, STAT3, PD-L1, BAX, Bcl-2, Cleaved Caspase-9, and Cleaved Caspase-3 were examined through Western blot analysis. In vivo experiments involved allocating mice into six groups (n = 5), including a saline control group, XJD treatment group (13.4 g/kg/day by gavage), αPD-L1 group (200 mg/mouse), Ruxolitinib group (10 mg/kg/day by gavage), XJD + Ruxolitinib group, and XJD + αPD-L1 group. Animal weight and tumor size were recorded daily for two weeks, and on day 18, the animals were sacrificed for tumor and spleen analysis. The number of macrophages present in the abdominal cavity, fresh tumors, and spleen was also measured.
RESULTS
XJD effectively inhibited cell growth, triggered apoptosis, and induced cell cycle arrest in NSCLC cells. XJD was shown to downregulate JAK1 expression, inhibit the phosphorylation of STAT3, and reduce PD-L1 protein levels. It also decreased Bcl-2 expression while increasing the levels of BAX, Cleaved Caspase-9, and Cleaved Caspase-3, promoting cell apoptosis. Furthermore, inhibiting STAT3 phosphorylation alongside XJD treatment further amplified cell growth inhibition, induced stronger apoptosis, and more effectively arrested the cell cycle. Additionally, XJD enhanced the anti-cancer efficacy of αPD-L1, with tumor growth inhibition linked to reduced M2 macrophage infiltration and increased M1 macrophage presence. Mechanistically, combination therapies incorporating XJD with either Ruxolitinib or αPD-L1 exhibited dual therapeutic effects: 1) promotion of tumor apoptosis through enhanced caspase activation, and 2) effective suppression of the oncogenic JAK1/STAT3 signalling axis and its downstream PD-L1 expression.
CONCLUSIONS
Our results indicate that XJD suppresses NSCLC cell growth, induces cell cycle arrest, and promotes apoptosis by inhibiting the JAK1/STAT3/PD-L1 signaling pathway. XJD has been shown to enhance the anti-cancer efficacy of αPD-L1 and exerts its anti-tumor effects by modulating macrophage polarization.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.